Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies.

被引：0
|
作者：
Ottmann, O
Giles, F
Wassmann, B
Hochhaus, A
Rae, P
Beran, M
Albitar, M
Alland, L
Dugan, M
Kantarjian, H
机构：
[1] Univ Frankfurt, D-6000 Frankfurt, Germany
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Quest Diagnost, San Juan Capistrano, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195S / 195S
页数：1
相关论文
共 50 条
  • [31] Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects.
    Kagan, M
    Tran, P
    Fischer, V
    Savage, P
    Smith, T
    Tanaka, C
    Schran, H
    Narurkar, M
    Alland, L
    BLOOD, 2005, 106 (11) : 302B - 302B
  • [32] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP).
    Kantarjian, H. M.
    Gattermann, N.
    O'Brien, S. G.
    Bhalla, K.
    Hochhaus, A.
    Cervantes, F.
    Alland, L.
    Ottmann, O.
    Giles, F.
    Le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 345S - 345S
  • [33] Bcr-Abl mutations in imatinib-resistant CML and Ph plus ALL patients (pts) enrolled in a phase I study of AMN107.
    Ottmann, O.
    Bhalla, K.
    Kantarjian, H.
    Hochhaus, A.
    Jones, D.
    Dawson, K.
    Rose, K.
    Alland, L.
    Dugan, M.
    Lilleburg, S.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [34] ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
    J Wu
    F Meng
    Y Ying
    Z Peng
    L Daniels
    W G Bornmann
    A Quintás-Cardama
    D Roulston
    M Talpaz
    L F Peterson
    N J Donato
    Leukemia, 2010, 24 : 869 - 872
  • [35] ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
    Wu, J.
    Meng, F.
    Ying, Y.
    Peng, Z.
    Daniels, L.
    Bornmann, W. G.
    Quintas-Cardama, A.
    Roulston, D.
    Talpaz, M.
    Peterson, L. F.
    Donato, N. J.
    LEUKEMIA, 2010, 24 (04) : 869 - 872
  • [36] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Weisberg, Ellen
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Hochhaus, Andreas
    Griffin, James D.
    NATURE REVIEWS CANCER, 2007, 7 (05) : 345 - U5
  • [37] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
    Hasanova, Aypara
    Asadov, Chingiz
    Karimova, Nigar
    Shirinova, Aytan
    Aliyeva, Gunay
    Alimirzoyeva, Zohra
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [38] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Ellen Weisberg
    Paul W. Manley
    Sandra W. Cowan-Jacob
    Andreas Hochhaus
    James D. Griffin
    Nature Reviews Cancer, 2007, 7 : 345 - 356
  • [39] Imatinib-resistant BCR-ABL mutations alter oncogenic potency, kinase activity and substrate selection.
    Gorre, ME
    Skaggs, BJ
    Sawyers, CL
    BLOOD, 2004, 104 (11) : 161A - 161A
  • [40] Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells
    Kim, J. E.
    Yoon, S.
    Choi, B-R
    Kim, K. P.
    Cho, Y-H
    Jung, W.
    Kim, D-W
    Oh, S.
    Kim, D-E
    LEUKEMIA, 2013, 27 (08) : 1650 - 1658
12345